

PreveCeutical Medical Inc

23:25 21 May 2019

PreveCeutical Medical wins approval to acquire human tissue for final phase of Sol-gel technology testing

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) revealed Tuesday that its Sol-gel drug delivery research and development (R&D) program is set to be boosted as the firm has received approval to acquire human nasal tissue for the final phase of testing the technology.

The company said PreveCeutical's research team at the University of Queensland has been granted the necessary approvals from a local hospital's human ethics committee.

Investors cheered the news, sending the stock up nearly 22.3% to \$0.056 in the OTC Markets.

READ: PreveCeutical Medical applies to acquire human tissue for next phase of Sol-gel technology testing

The health-sciences group is developing the first, sustained-release, Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids aimed at providing relief for pain, inflammation, seizures and neurological disorders.

"Getting approval to acquire and use human mucosal tissue for this final phase of the Sol-Gel program allows us work on a proof of concept for Sol-Gel delivery in a laboratory setting," said the company's Chief Science Officer Dr Mak Jawadeka in a statement.

Sol-gels are taken via the nose and rapidly gel upon contact with mucosal tissue.

Using an adult human nasal cast, PreveCeutical earlier demoed that the company's cannabinoid-based Sol-gel is delivered and retained directly at "the target tissue," high in the nasal cavity when administered with a Sol-gel applicator device.

R&D intensive

Preveceutical currently has five research and development programs.

These are for dual gene therapy for curative and prevention therapies for diabetes and obesity, the Sol-gel program, Nature Identical peptides for treatment of various ailments.

It is also advancing non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone, and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

In July 2018, the firm launched its CBD division, which focuses on finding treatments for various ailments using CBD, which can be administered through the Sol-gel delivery system. The Sol-gel delivery system uses a sustained-release

Price: C\$0.04

Market Cap: C\$15.86M

1 Year Share Price Graph



Share Information

Code: PREV

Listing: CSE

52 week High Low
C\$0.17 C\$0.03

Sector: Health Care, Equipment & Services

Website: preveceutical.com

Company Synopsis:

PreveCeutical Medical Inc is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Author:

Proactive Investors Australia

+61 (0)2 9280 0700

action@proactiveinvestors.com.au

nose-to-brain delivery system, designed to be universally-patient friendly, meaning that formulations could be used in both children and adults.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek personal advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.